In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company …
NASDAQ1mon
Shares of Bristol-Myers Squibb Co. (ticker: BMY) fell more than 16 percent Friday after the company announced that its Opdivo drug failed a study that would have expanded its use to lung cancer patients. BMY stock dropped more than …
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …
Its stock traded above $40 in mid-2015 ... The results could affect sales of Merck's drug Keytruda and Bristol-Myers Squibb's Opdivo. Merck fell $1.10, or 2 percent, to $54.10 and Bristol-Myers Squibb lost 52 cents to $60.80. The …
news that hit Bristol-Myers stock hard and buoyed Merck's shares. Leerink analyst Seamus Fernandez said Keytruda's results support Merck's assertion of a "sea change" in this area of cancer treatment. "The nearly inexplicable failure of …
Bristol-Myers Squibb's stock fell nearly 10 percent yesterday after the company released a disappointing earnings forecast. The news helped send the prices of other drug stocks tumbling. . The shares of the Bristol-Myers Squibb …
Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment …
Those worries largely evaporated, though, and BMS stock eventually went on to generate nice year-to-date gains. Now, however, worries are resurfacing. Bristol-Myers Squibb announced its third-quarter results before the market opened on …
Bristol-Myers Squibb Company (NYSE: BMY) and Mead Johnson Nutrition Company (NYSE: MJN) announced today …